Scryb Inc. Forum: Community User: Philipp85

Langsam aber sicher kommt das vertrauen wieder zurück

Laut der DiBa selbst ist die Order möglich. Einfach online in Service, Kontakt, Auftrag. Man muss bestätigen dass man von der DiBa die BaFin Meldung bekommen hat, diese zur Kenntnis genommen hat, und sich der möglichen Folgen bewusst ist. Dann muss man schreiben welche Stückzahl zu welchem Kurs zu welchem Limit man kaufen möchte. Laut Diba wird die Order dann, wenn möglich, ausgeführt.

@MR1987 ich habe zusätzlich zur DiBa ein Depot bei Comdirect: komplett kostenlos, handeln ChromedX und für neue Depots kann man zur Zeit ein Jahr lang für 3,90€ traden...

@Derebse, weil ich sie in englisch per e-mail bekommen hatte und keine Zeit hatte noch zu google'n, zu dem Zeitpunkt gab es die news hier noch nicht und ich hab sie schnell rein kopiert...als Wissensvorsprung, da nicht alle im newsletter von Chromedx eingetragen sind, wurde leider alles reinkopiert..

Nein. Bei der diba gibt es einfach ne kaufsperre für 3 Monate. Telefonisch auch schon versucht

Danny, warum postest du die ganzen News in Englisch? Die sieht doch jeder in der App unter news- und sogar in Deutsch.

Telefonisch bzw. per Mail kannst du doch deine Order platzieren

Alles schon versucht

Ruf doch an und sag bei anderen Providern gehts! Du wechselst sonst, du musst bei denen einfach Druck machen.

Leider gibt's bei der diba immer noch die kaufsperre. Die a.....r

Läuft

https://www.chromedx.com/chromedx-corp-expands-executive-team-lahav-gil-appointed-ceo-and-director

Toller Anstieg... kann so weiter gehen

So heißt der wohl wirklich ;-)

Clark Kent???

ChroMedX Corp. Expands Executive Team;Lahav Gil Appointed CEO and Director   January 05, 2018 – ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: CHXIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the appointments of MedTech visionary Lahav Gil as Chief Executive Officer and W. Clark Kent as President of the Company. Both have also been appointed to the Company’s board of directors.   Mr. Gil joins ChroMedX as the founder and former CEO of the innovative Toronto-based medical device industrial design and productization organization, Kangaroo Group (ISO 13485). Lahav founded the company in 2003 and evolved it into a full-spectrum outsourcing platform for Medical Device innovation, engineering, design, productization, RA submissions and contract manufacturing, contributing to many product launches in the Canadian and international MedTech industry. Kangaroo was acquired by full service medical device design company Starfish Medical in April of 2017.   “Lahav’s achievements speak for themselves but his energy, vision and passion for design and development is something truly remarkable.” said Gerard Edwards, Executive Chairman, ChroMedX Corp. “This appointment is an exciting milestone in a plan that the board of directors have been working on for quite sometime. We are proud to appoint Lahav as CEO and welcome him to the board of directors.”   Lahav is well known in the community for his strong team building abilities and emphasis on innovation culture, as well as his track record as a MedTech entrepreneur, design-driven innovator, and business leader.    “With the HemoPalm, ChroMedx is well positioned to bring a remarkable and critically needed product to market.” said Lahav Gil, CEO & Director, ChroMedX Corp. “Successful commercializing of a medical device relies on a deep and profound understanding of the problems that you are trying to solve at all levels of the product and business offering. Critically understanding the requirements of all the stakeholders including those leading to a strategic acquisition are key to this success, as well as designing for frictionless adoption models, a superior user experience, and a robust supply chain. It is essential to build a team and corporate culture that intuitively and strategically understands these concepts and loves working together on meaningful innovation and I am very excited to join ChroMedX and lead this process.”   W. Clark Kent has been appointed President and joined the ChroMedX board of directors. Clark is a capital markets professional with extensive experience leading corporate development and finance initiatives in the life sciences, technology and natural resource industries. For over a decade he has advised emerging companies on strategic planning, finance and recruitment in the North American and international marketplace.   “As a long-time supporter and consultant Clark has been instrumental in the advancement of ChroMedX and the HemoPalm technology.” said Gerard Edwards, Executive Chairman, ChroMedX Corp. “Clark has most recently been responsible for the Company’s partnership with DxEconomix and introduction to Lahav Gil. We are very pleased to now welcome him as a director and fulltime member of the team as ChroMedX President.”   With the appointments of Mr. Gil and Mr. Kent, Ash Kaushal will step down from his President, CEO and Director roles. Mr. Kaushal joined the Company as President and CEO in July 2016 after serving as a key consultant since the Company’s inception. The ChroMedX board of directors would like to thank Ash for his contributions and leadership in 2017. Mr. Kaushal will continue to work with the Company on a consulting basis.   With these appointments ChroMedX has increased its board to 6 directors. Further information on the Company’s executive team, board of directors and key advisors can be found at www.chromedx.com   About Lahav Gil   Lahav is the founder and former CEO of the Toronto based Kangaroo Group, which he built into a national brand and recently sold to Starfish Medical of Vancouver Island. He is passionate about meaning, loves Innovation Culture, Values-Based Leadership, transparency & awareness.    Lahav has deep experience in Medtech product development and business. He has founded/co-founded 6 companies and has accompanied many Canadian start-ups on their journey from napkin to launch, critically contributing to their investability, clinical and market readiness. He has contributed to over 200 technology product launches and to game-changing innovations for companies such as: IMRIS, FIO, fSona, Cellaegis, XOR, Ultrasonix, Exact Imaging, Sciex, and others.   For almost 3 decades, he has been involved with tech-innovation, entrepreneurship, and start-up companies, starting in Israel’s bustling innovation climate of the 80's. During the late 90's Lahav integrated into the Canadian innovation scene, leading Industrial Design projects and corporate-wide iD strategy for Creo/Kodak in Vancouver, where he first got a taste of the crucial role of culture in business. In 2003 he founded Kangaroo Design, which he evolved into the Kangaroo Group (ISO 13485), a full-spectrum outsourcing platform for Medical Devices innovation, engineering, design, productization, RA submissions and contract manufacturing.   Under his leadership, Kangaroo supplied services, infrastructure, and incubation partnerships to Canadian Medtech startups and entrepreneurs for over 15 years. During this time, Lahav’s main focus was building Kangaroo as a platform alongside spin-ins, spin-outs & incubation-investments.   Recent News   ChroMedX most recently announced the signing of a definitive agreement with diagnostics marketing experts DxEconomix to lead initiatives relating to potential high-value transactions. Further information can be found on the Company’s website.   Website   Investors and individuals interested in keeping abreast of latest news and updates can subscribe on the Home and News pages on the Company's website at www.ChroMedX.com